Targeting Breast Cancer Stem Cells
Posted by WH in News, tags: cancer stem cells, oncology, target identification
Image: Flickr – BK1Bennett
In this latest study the team identified overexpression of CXCR1, the receptor for interleukin-8 (IL-8), by the CSC subpopulation in a breast cancer cell line. Furthermore, addition of recombinant IL-8 increased the CSC population and enhanced the propensity for invasion. Conversely, use of CXCR1-blocking antibodies or repertaxin, a small-molecule CXCR1 antagonist, selectively depleted the breast CSCs both in vitro and in murine xenograft models.
CXCR1 blockade also induced massive apoptosis in bulk tumour cells, mediated by FASL/FAS signalling. The effects on CSC viability as well as FASL production were mediated by the focal adhesion kinase/AKT/forkhead transcription factor FKHRL1 (FAK/AKT/FOXO3A) pathway. Importantly, administration of repertaxin reduced tumour growth and the development of systemic breast cancer metastasis in NOD/SCID mice.
The authors of the study, published in the Journal of Clinical Investigation, suggest blockade of CXCR1 as a novel target for depletion of CSCs, potentially enhancing the efficacy of chemotherapeutic regimes.
Related posts:
- Salinomycin Selectively Attacks Breast Cancer Stem Cells There is growing evidence for a subpopulation of cells in breast cancer, known as breast cancer stem cells, that may...
- Suppressing ROCK May Prevent Breast Cancer Metastases Nearly half of all patients treated for apparently localised breast cancer develop metastatic disease. Although there are treatment options that...
- Targeting Cancer Stem Cells Cancer stem cells are slowly dividing tumourigenic cells that possess characteristics of normal stem cells. It has been proposed that...
- Targeting ‘Normal’ Cells to Treat Cancer Most cancer treatments directly target the cancerous cells but tumours are a heterogeneous mix of transformed cells and ‘normal’ cells....
- Syk Protective Against Breast Cancer Inhibitors of the non-receptor spleen tyrosine kinase (Syk) are being developed to treat a variety of allergic and autoimmune disorders,...
Related posts brought to you by Yet Another Related Posts Plugin.
This entry was posted on Wednesday, January 6th, 2010 at 9:56 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.















Entries (RSS)